The regulatory environment for compounded GLP-1 therapies has tightened significantly
Fill-finish and device manufacturing After API is produced (as bulk drug substance), Novo conducts formulation, filling into injection devices, and assembly/packaging largely in-house
The new weight loss injections are Wegovy, Ozempic, and Mounjaro
As of January 6, 2025 here is a list of approved and pending new GLP-1 agonists class of medications that can help manage Type 2 diabetes and obesity: Ozempic (semaglutide) Approved - A weekly injectable GLP-1 receptor agonist that helps regulate blood sugar and suppress appetite, promoting weight loss in addition to managing type 2 diabetes
The difference is the brand name, not the efficiency of the drug
4 - Ongoing Care Your care team checks in every 2 weeks via text